Monitor for follow-on dilution risk and track progress toward breakeven cash flow by year-end; insider buying suggests confidence, but small cap and repeated financings indicate high execution risk.
Price Chart
Executive Summary
Vivos Therapeutics closed a $2.25 million private placement with V-Co Investors 3 LLC, an affiliate of New Seneca Partners, including the conversion of a $1.4 million bridge note. The funds will be used for working capital as the company executes its shift toward medical practice affiliations and aims for breakeven cash flow by end of 2026.
Key Financial Metrics
Key Facts
- Vivos Therapeutics (VVOS) raised $2.25 million in a private placement closed on March 31, 2026.
- Proceeds include conversion of a $1.4 million bridge note (pre-OID), with total gross proceeds excluding a $140,000 original issue discount.
- Investor V-Co 3 received common stock, a pre-funded warrant, and two common stock purchase warrants (2-year and 5-year), all exercisable at $1.09 per share.
- Purchase price per unit was $1.34, set to comply with Nasdaq listing rules.
- Since 2024, Seneca affiliates have invested $13.4 million in Vivos.
- Proceeds will be used for general working capital; company aims for breakeven operating cash flow by end of 2026.
Financial Impact
$2.25 million gross proceeds, dilutive financing with warrants issued at $1.09 strike price
Risk Factors
- Dilution from issuance of common stock and multiple warrants exercisable at $1.09
- Failure to achieve breakeven cash flow by end of 2026 as targeted
- Dependence on continued support from a single investor group (Seneca affiliates)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $0.1347 | awaiting T+60 | — | $0.1283 (−4.75%) |
Oct 19, 2026 8d ago | Press Release | $0.1410 | awaiting T+60 | — | $0.1283 (−9.01%) |
Oct 19, 2026 8d ago | 8-K | $0.1406 | awaiting T+60 | — | $0.1283 (−8.75%) |
Oct 15, 2026 12d ago | 8-K | $0.1428 | awaiting T+60 | — | $0.1283 (−10.15%) |
Oct 15, 2026 12d ago | Press Release | $0.1428 | awaiting T+60 | — | $0.1283 (−10.15%) |
Sep 30, 2026 26d ago | 8-K | $0.1490 | awaiting T+60 | — | $0.1283 (+13.89%) |
Aug 28, 2026 8w ago | Press Release | $0.2249 | awaiting T+60 | — | $0.1283 (−42.95%) |
Aug 21, 2026 9w ago | 8-K | $0.2768 | awaiting T+60 | — | $0.1283 (−53.65%) |
Aug 14, 2026 10w ago | Press Release | $0.3012 | awaiting T+60 | — | $0.1283 (+57.40%) |
Aug 14, 2026 10w ago | Press Release | $0.3433 | awaiting T+60 | — | $0.1283 (−62.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers